Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Rhovac board member resigns due to health reasons 2022-10-18 21:29
Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers 2022-05-19 00:40
RhoVac AB announces Database Lock in its clinical phase IIb trial of onilcamotide 2022-05-11 06:42
RhoVac retains international investment bank as advisor for desired RV001 transaction 2021-10-11 14:57
RhoVac presents 3-year follow-up results of the phase I/II study in prostate cancer 2021-10-05 19:14
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer 2021-04-21 20:56
Global Covid-19 Vaccination Roll-out causes delay to RhoVac's Phase IIb study 2021-03-09 02:41
First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom 2021-01-07 22:40
Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer 2020-11-13 17:53
First patient in treatment in RhoVac's clinical phase IIb study in Sweden 2020-09-17 23:51
RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board 2020-09-04 17:35
First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany 2020-04-24 00:37
1